Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: A population-based study

American Journal of Geriatric Psychiatry

Volumn 22, Issue 4, 2014, Pages 321-331

  Langballe, Ellen Melbye ^a   Engdahl, Bo ^a   Nordeng, Hedvig ^a,d   Ballard, Clive ^e   Aarsland, Dag ^f,g   Selbæk, Geir ^b,c  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b INNLANDET HOSPITAL TRUST   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f STAVANGER UNIVERSITY HOSPITAL   (Norway)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antidementia drugs; Antipsychotic drugs; Mortality; Norwegian Prescription Database

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ASENAPINE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; LITHIUM; NEUROLEPTIC AGENT; NOOTROPIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PROCHLORPERAZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL;

AGED; ARTICLE; COMORBIDITY; DATA BASE; DEMENTIA; DISEASE SEVERITY; DRUG USE; FOLLOW UP; HAZARD RATIO; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MORTALITY; OUTPATIENT; PHARMACY; PHYSICIAN; PRESCRIPTION; RISK ASSESSMENT; TREATMENT DURATION;

ANTIDEMENTIA DRUGS; ANTIPSYCHOTIC DRUGS; MORTALITY; NORWEGIAN PRESCRIPTION DATABASE;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DEMENTIA; FEMALE; HALOPERIDOL; HUMANS; LONGITUDINAL STUDIES; MALE; NORWAY; PROPORTIONAL HAZARDS MODELS; RISPERIDONE; SURVIVAL ANALYSIS;

EID: 84898608517     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2013.06.007     Document Type: Article

References (42)

1. Steinberg M, Shao H, Zandi P, et al: Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2007; 23:170-177
2. Selbaek G, Kirkevold O, Engedal K: The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes-a 12-month follow-up study. Am J Geriatr Psychiatry 2008; 16: 528-536
3. Trifirò G, Spina E, Gambassi G: Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res 2009; 59:1-12
4. Seitz DP, Gill SS, Herrmann N, et al: Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. Int Psychogeriatr 2013; 25:185-203
5. Muench J, Hamer AM: Adverse effects of antipsychotic medications. Am Fam Physician 2010; 81:617-622
6. U.S.Food and Drug Administration. FDA requests boxed warnings on older class of antipsychotic drugs 2008. Available at: http:// www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ 2008/ucm116912.htm
7. Musicco M, Palmer K, Russo A, et al: Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease. Dement Geriatr Cogn Disord 2011; 31:218-224
8. Kales HC, Valenstein M, Kim HM, et al: Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007; 164:1568-1576
9. Liperoti R, Onder G, Landi F, et al: All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry 2009; 70:1340-1347
10. Raivio MM, Laurila JV, Strandberg TE, et al: Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry 2007; 15:416-424
11. Livingston G, Walker AE, Katona CL, et al: Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study. J Neurol Neurosurg Psychiatry 2007; 78:25-29
12. Rossom RC, Rector TS, Lederle FA, et al: Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc 2010; 58: 1027-1034
13. Kales HC, Kim HM, Zivin SDK, et al: Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2012; 169:71-79
14. Huybrechts KF, Gerhard T, Crystal S, et al: Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012; 344:e977
15. Marras C, Gruneir A, Wang X, et al: Antipsychotics and mortality in parkinsonism. Am J Geriatr Psychiatry 2012; 20:149-158
16. Hollis J, Grayson D, Forrester L, et al: Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. Am J Geriatr Psychiatry 2007; 15:932-941
17. Simoni-Wastila L, Ryder PT, Qian J, et al: Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry 2009; 17:417-427
18. Gardette V, Lapeyre-Mestre M, Coley N, et al: Antipsychotic use and mortality risk in community-dwelling Alzheimer's disease patients: evidence for a role of dementia severity. Curr Alzheim Res 2012; 9:1106-1116
19. Schneider LS, Dagerman KS, Insel PS: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-1943
20. Wang PS, Schneeweiss S, Avorn J, et al: Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med 2005; 353:2335-2341
21. Gill SS, Bronskill SE, Normand SL, et al: Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146:775-786
22. Barnes TRE, Banerjee S, CollinsN, et al: Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services. Br J Psychiatry 2012; 201:221-226
23. Gruber-Baldini AL, Stuart B, Zuckerman IH, et al: Treatment of dementia in community-dwelling and institutionalized medicare beneficiaries. J Am Geriatr Soc 2007; 55:1508-1516
24. Kavirajan H, Schneider LS: Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007; 6:782-792
25. Ballard C, Howard R: Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 2006; 7:492-500
26. The Norwegian Directorate of Health. Glemsk, men ikke glemt. Om dagens situasjon og framtidas utfordringer for a styrke tjenestetilbudet til personer med demens, 2007, page 44. [In Norwegian] Available at: http://www. helsedirektoratet.no/publikasjoner/glemskmen-ikke-glemt-rapport-om-demens/ Publikasjoner/glemsk-menikke-glemt.pdf. Accessed April 12, 2012
27. Statistics Norway: Bebuarar i institusjonar for eldre og funksjonshemma, etter alder, 1992-2011 [Number of people in Norway living in institutions for old or disabeled people, by age, 1992-2011]. [In Norwegian] Available at: http://www.ssb.no/a/ kortnavn/pleie/tabe2012-07-04-02.html. Accessed April 12, 2013
28. Selbaek G, Kirkevold O, Engedal K: The prevalence of psychiatric symptoms and behavioral disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psychiatry 2007; 22:843-849
29. Langballe EM, Engdahl B, Seabaek G, et al: Concomitant use of antidementia drugs with psychotropic drugs in Norway-a population-based study. Pharmacoepidemiol Drug Saf 2011; 20: 1319-1326
30. Cause of Death Registry 2012: Available at: http://www.fhi.no/eway/ default.aspx?pid=233&trg=Area-5774&MainArea-5661=5631:0:15, 4439:1:0:0:::0:0&MainLeft-5631=5774:0:15, 4439:1:0:0:::0:0&Area-5774= 5544:86276::1:5776:1:::0:0
31. Rønning M, Berg Ch, Litleskare I, et al: The Norwegian Prescription Database 2004-2008 (report no. 2009:1). In: Legemiddelstatistikk 2009:2 Reseptregisteret. Oslo, Norway, Norwegian Institute of Public Health, 2009
32. The Norwegian Labour and Welfare Administration: Kontrollordningen for bla resept. Kontroll av legers forskrivning pa refusjonspunkt 7i. Demens. Lokal kontroll nr 1/2005. [Control of physicians prescription of dementia drugs according to reimbursement regulation 7i.] Available at: http://www.helfo.no/ SiteCollectionDocuments/Vedlegg%20helsepersonell/Bl%C3%A5 reseptkontroller/ Kontroll%209%20fra%202005%20Refusjonspun kt%207i,%20regional.pdf.pdf. Accessed May 1, 2010
33. Nasrallah HA, White T, Nasrallah AT: Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data. Am J Geriatr Psychiatry 2004; 12:437-439
34. Sacchetti E, Trifirò G, Caputi A, et al: Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol 2008; 22:39-46
35. Gassó P, Mas S, Molina O, et al: Neurotoxic/neuroprotective activity of haloperidol, risperidone, and paliperidone in neuroblastoma cells. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36:71-77
36. Gentile S: Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. Psychopharmacology 2010; 212:119-129
37. U.S. National Library of Medicine: Prochlorperazine. Available at: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682116.html
38. Caughey GE, Roughead EE, Pratt N, et al: Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing? Pharmacoepidemiol Drug Saf 2010; 19:977-982
39. Rani Basu L, Mazumdar K, Kumar Dutta N, et al: Antibacterial property of the antipsychotic agent prochlorperazine, and its synergism with methdilazine. Microbiol Res 2005; 160: 95-100
40. Clemons A, Vasiadi M, Kempuraj D, et al: Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: possible relevance to chronic fatigue syndrome. J Clin Psychopharm 2011; 31:385
41. Ballard C, Creese B, Corbett A, et al: Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Exp Opin Drug Safety 2011; 10:1-9
42. NICE and SCIE (2006) Dementia: Supporting People with Dementia and their Carers in Health and Social Care. NICE clinical guideline. Available at www.nice.org.uk/CG42